Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elgene Lim

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
NPJ Breast Cancer|June 8, 2026
SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancerFrançois-Clement Bidard, Carlos Barrios, Giampaolo Bianchini, et al.
Nature Communications|August 6, 2022
Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasisMichael Papanicolaou, Amelia L Parker, Michelle Yam, et al.
The New England Journal of Medicine|December 11, 2024
Imlunestrant with or without Abemaciclib in Advanced Breast CancerKomal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, et al.
Nature Genetics|September 8, 2021
A single-cell and spatially resolved atlas of human breast cancersSunny Z Wu, Ghamdan Al-Eryani, Daniel Lee Roden, et al.
The New England Journal of Medicine|January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast CancerOtto Metzger, Sumithra Mandrekar, Shom Goel, et al.
Nature Communications|May 11, 2026
Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signallingKristine J Fernandez, Ghazal Sultani, Max Nobis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Science Advances|May 1, 2023
Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouseJames R W Conway, Sean C Warren, Young-Kyung Lee, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2024
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid MetabolismElysse C Filipe, Sipiththa Velayuthar, Ashleigh Philp, et al.
Cancer Discovery|June 9, 2025
Federated Deep Learning Enables Cancer Subtyping by ProteomicsZhaoxiang Cai, Emma L Boys, Zainab Noor, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
NPJ Breast Cancer|June 8, 2026
SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancerFrançois-Clement Bidard, Carlos Barrios, Giampaolo Bianchini, et al.
Nature Communications|August 6, 2022
Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasisMichael Papanicolaou, Amelia L Parker, Michelle Yam, et al.
The New England Journal of Medicine|December 11, 2024
Imlunestrant with or without Abemaciclib in Advanced Breast CancerKomal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, et al.
Nature Genetics|September 8, 2021
A single-cell and spatially resolved atlas of human breast cancersSunny Z Wu, Ghamdan Al-Eryani, Daniel Lee Roden, et al.
The New England Journal of Medicine|January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast CancerOtto Metzger, Sumithra Mandrekar, Shom Goel, et al.
Nature Communications|May 11, 2026
Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signallingKristine J Fernandez, Ghazal Sultani, Max Nobis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Science Advances|May 1, 2023
Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouseJames R W Conway, Sean C Warren, Young-Kyung Lee, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2024
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid MetabolismElysse C Filipe, Sipiththa Velayuthar, Ashleigh Philp, et al.
Cancer Discovery|June 9, 2025
Federated Deep Learning Enables Cancer Subtyping by ProteomicsZhaoxiang Cai, Emma L Boys, Zainab Noor, et al.
Pageof 13